Gleicher, Norbert
Darmon, Sarah K.
Patrizio, Pasquale
Barad, David. H.
Funding for this research was provided by:
The Center for Human Reproduction
The Foundation for Reproductive Medicine
Article History
Received: 3 March 2023
Accepted: 29 August 2023
First Online: 11 September 2023
Declarations
:
: All patients consented to the use of their medical records for research purposes, as long as those records were anonymized, prohibiting their identification. Since this study only involved anonymized electronic medical records and this condition, therefore, was met, this study was approved by the center’s IRB in expedited format.
: Not applicable.
: N.G. and D.H.B. are listed as co-owners of several already awarded and still pending U.S. patents, some claiming benefits from androgen supplementation in women with low functional ovarian reserve, a topic addressed in this manuscript. Others relate to diagnostic and potential therapeutic benefits of AMH, also marginally addressed in this manuscript. N.G. is a shareholder in Fertility Nutraceuticals, LLC, which produces a DHEA product, and is the owner of The CHR., where much of the research reported in this manuscript was performed. N.G. and D.H.B. also receive patent royalties from Fertility Nutraceuticals, LLC. N.G. and D.H.B. in the past have received research support, travel funding, and lecture fees from various Pharma and medical device companies, none, however, over the last three years and none in any way related to this manuscript.